Evaluating Anti-Tumor Efficacy of Cetuximab and MM-121 in Xenograft Model
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Sun Yat-sen University, Sun Yat-sen University Cancer Center, Emory University, Quest Diagnostics (United States), Merrimack Pharmaceuticals (United States)
Protocol cited in 2 other protocols
Variable analysis
- Cetuximab 6.25μg/dose
- MM-121 300μg/dose (MM-121.LD)
- MM-121 600μg/dose (MM-121.HD)
- Combination with low dose MM-121 (comb. LD)
- Combination with high dose MM-121 (comb. HD)
- Tumor volume
- Bodyweight
- Female nude mice (athymic nu/nu, Taconic, NY) aged 4 to 6 weeks
- Subcutaneous injection of 4×10^6 Tu212 and 2×10^6 SCC47 cells (1:1 in matrigel)
- PBS control
- Positive control: PBS control
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!